Description
Release form
Capsules
Pharmacological action
Meldonium is a structural analogue of gamma-butyrobetaine – a substance that is present in every cell of the human body.
Meldonium inhibits gamma-butyrobetaine hydroxygenase, reduces the synthesis of carnitine and the transport of long chain fatty acids through cell membranes, and prevents the accumulation of activated forms of unoxidized fatty acids in the cells – derivatives of acylcarnitine and acylcoenzyme A. In conditions of ischemia, it restores the balance of the processes of oxygen delivery and its consumption in cells, prevents the violation of the transport of adenosine triphosphoric acid (ATP). At the same time, it activates glycolysis, which proceeds without additional oxygen consumption. As a result of a decrease in carnitine concentration, gamma-butyrobetaine with vasodilating properties is intensely synthesized. The mechanism of action determines the diversity of its pharmacological effects: increasing efficiency, reducing symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect.
In case of acute ischemic damage to the myocardium, it slows down the formation of the necrosis zone and shortens the rehabilitation period. With heart failure improves myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the focus of ischemia.
Effective in case of ocular fundus vascular pathology.
The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism during withdrawal.
Indications
– as part of the complex therapy of coronary heart disease (angina pectoris, myocardial infarction) of chronic heart failure, dishormonal cardiomyopathy
– as part of the complex therapy of acute cerebrovascular accident (ischemic stroke, cerebrovascular insufficiency, acute sr . in athletes)
– withdrawal syndrome in chronic alcoholism (in combination with specific therapy)
– hemophthalmus and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertension).
Contraindications
hypersensitivity
increased intracranial pressure (with impaired venous outflow and intracranial tumors)
pregnancy
lactation
children under 18 years of age.
Precautions: liver and / or kidney disease.
Use during pregnancy and lactation
The safety of the drug during pregnancy has not been proven. In order to avoid a possible adverse effect on the fetus, the drug should not be prescribed during pregnancy.
It is not known whether this drug is excreted in breast milk. If it is necessary to use the drug Idrinol during lactation, breastfeeding should be discontinued.
Special instructions
Idrinol is not a first-line drug for acute coronary syndrome.
Influence on the ability to drive vehicles and mechanisms
Data on the adverse effects of the drug Idrinol on the speed of psychomotor reactions are not available.
Dosage and Administration
Inside.
Disturbance of cerebral circulation: in the acute phase of cerebrovascular pathology, an injection form of the drug is used for 10 days, after which it is administered orally at 500 mg / day. The course of treatment is 4-6 weeks.
Chronic cerebrovascular accident: 500 mg / day, preferably in the morning. The course of treatment is 4-6 weeks. Repeated courses – 2-3 times a year.
In cardiology in complex therapy: 0.51 g per day. The course of treatment is 4-6 weeks.
Cardialgia on the background of dishormonal myocardial dystrophy: 250 mg 2 times a day (morning and evening). The course of treatment is 12 days.
Mental and physical overload (incl. athletes): adults 250 mg 4 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.
0.51 g 2 times a day before training, preferably in the morning. The duration of the course in the preparatory period is 14-21 days, during the competition period 10-14 days.
Withdrawal alcohol syndrome: 500 mg 4 times a day. The course of treatment is 7-10 days.
Side effects of
From the cardiovascular system: rarely – tachycardia, decreased or increased blood pressure.
From the side of the central nervous system: rarely – psychomotor agitation.
From the digestive system: rarely – dyspeptic disorders.
Allergic reactions: rarely – itching, rash, flushing of the skin, angioedema very rarely – eosinophilia.
Others: very rarely – general weakness.
Drug Interactions
Can be combined with antianginal agents, anticoagulants, antiplatelet agents, antiarrhythmic drugs, diuretics, bronchodilators.
Enhances the action of cardiac glycosides.
Due to the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, antihypertensive drugs, and peripheral vasodilators.
Overdose
Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment: symptomatic.
Storage conditions
The product should be stored out of the reach of children at a temperature not exceeding 25 ° C. Do not freeze.
Term hodnosty
5 years
active substance
meldonium
Terms leave through pharmacies
In retseptu
lekarstvennaja form
kapsul
